Teva Pharmaceutical Industries Ltd said on Tuesday it would stop developing its migraine drug, Ajovy, for treating cluster headaches after the company found the treatment was unlikely to meet the main goal of a late-stage trial.
from Reuters: Health News https://reut.rs/2W4zPdw
via IFTTT
from Reuters: Health News https://reut.rs/2W4zPdw
via IFTTT
إرسال تعليق